Current Advances in ACE Inhibition: v.2
Churchill Livingstone (Publisher)
2nd Edition
Published in October 1991
Book
Hardback
324 pages
978-0-443-04600-1 (ISBN)
Description
A review of issues relating to ACE inhibition, outlining research and developments in this area. This text should be of interest to cardiologists.
A review of issues relating to ACE inhibition, outlining research and developments in this area. This text should be of interest to cardiologists.
A review of issues relating to ACE inhibition, outlining research and developments in this area. This text should be of interest to cardiologists.
More details
Series
Edition
2nd ed.
Language
English
Place of publication
London
United Kingdom
Publishing group
Elsevier Health Sciences
Target group
Professional and scholarly
Illustrations
30 line drawings, 50 half-tones
Dimensions
Height: 22 mm
Width: 253 mm
Weight
945 gr
ISBN-13
978-0-443-04600-1 (9780443046001)
Copyright in bibliographic data is held by Nielsen Book Services Limited or its licensors: all rights reserved.
Schweitzer Classification
Other editions
Previous edition
Macgregor | Peter S. Sever
Current Advances in Ace Inhibition II
Book
10/1991
Churchill Livingstone
€34.05
Article exhausted; check for reprint
Content
Part 1 State of the art: modulation of sympatho-adrenal function by the renin angiotensin system; the interaction of the renin angiotensin system with atrial peptides; the renal effects of ACE inhibition; renoprotective effects of ACE inhibitionC; hypertension and diabetes - familial and environmental factors in the genesis of renovascular complications; renoprotective actions of ACE inhibirots in diabetes mellitus; update on renovascular hypertension; ACE inhibitors - an update on heart failure trials; tissue ACE inhibition in humans; tissue RAS or paracrine RAS?; the actions of angiotensin 2 on vascular tone; indirect actions of angiotensin 2 on vascular tone; role of angiotensin 2 in growth regulation of vascular smooth muscle; effect of ACE inhibition treatment on vascular structure and compliance; therapeutic implications; active and passive response of arterial vasculature to ACE inhibition in human hypertension; the renin angiotensin system, its role in vascular cell growth; the use of transgenes to study the renin angiotensin system - present and future perspective; tissue renin-angiotensin systems - recent advances and new questions; molecular genetics of ACe - clinical implications; renin and prorenin - ounterpoised vasoconstrictor and vasodilator agents?; alternative ways to inhibit the renin angiotensin system - general overview; non peptide angiotensin 2 receptor antagonists; USA.. clinical investigation of renin inhibition; angiotensin 2, aldosterone and the heart - effects on growth and injury; angiotensin converting enzyme inhibitors and regression of left ventricular hypertrophy - is it clinically beneficial?; a role for ACe inhibitors in modulation ventricular remodelling and altering the course of heart dysfunction in ischaemia and myocardial infarction E/ future use of ACE inhibitors. Part 2 Free communications.